General Information of the Protein
| Protein ID |
PT00822
|
||||
|---|---|---|---|---|---|
| Protein Name |
Prothrombin
|
||||
| Secondarily Protein Name |
Coagulation factor II
|
||||
| Gene Name |
F2
|
||||
| Sequence |
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Enzyme
>
Protease
>
Serine protease
>
Serine protease PA clan
>
Serine protease S1A subfamily
|
||||
| Function |
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Subcellular Location |
Secreted
Extracellular space
|
||||
Map of Molecular Bioactivity Related to the Protein
|
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000044 , CV-1
| Compound ID | Compound Name | Compound Formula | |
| CP0026502 |
(2R)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
Show/Hide
|
C15H12I3NO4
|
1 |
| 1 |
EC50 = 1.2 nM
|
TI
LI
LO
TS
|
|
|---|---|---|---|
Cell Line ID: CL000011 , CHO
Cell Line ID: CL000265 , NS0
Cell Line ID: CL000090 , Schneider 2
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Coagulation factor IIa (F2) )
| Target Type | Successful Target | ||||
|---|---|---|---|---|---|
| Disease | 8 Target-related Diseases | 8 | |||
| 1 | Coagulation defect [ICD-11: 3B10.0] | ||||
| 2 | Thrombosis [ICD-11: DB61-GB90] | ||||
| 3 | Thrombocytopenia [ICD-11: 3B64] | ||||
| 4 | Stroke [ICD-11: 8B20] | ||||
| 5 | Malnutrition [ICD-11: 5B50-5B71] | ||||
| 6 | Myocardial infarction [ICD-11: BA41-BA43] | ||||
| 7 | Bleeding disorder [ICD-11: GA20-GA21] | ||||
| 8 | Neurological disorder [ICD-11: 6B60] | ||||
| Approved Drug(s) | 5 Approved Drugs | 5 | |||
| 1 | Anisindione | Approved | |||
| 2 | Argatroban | Approved | |||
| 3 | Bivalirudin | Approved | |||
| 4 | Dabigatran | Approved | |||
| 5 | Pyridoxal Phosphate | Approved | |||
| Clinical Trial Drug(s) | 4 Clinical Trial Drugs | 4 | |||
| 1 | LB-30870 | Phase 2 | |||
| 2 | AZD-8165 | Phase 1 | |||
| 3 | DP-4088 | Phase 1 | |||
| 4 | RWJ-671818 | Phase 1 | |||
| Discontinued Drug(s) | 9 Discontinued Drugs | 9 | |||
| 1 | Ximelagatran | Withdrawn from market | |||
| 2 | INOGATRAN | Discontinued in Phase 2 | |||
| 3 | Napsagatran | Discontinued in Phase 2 | |||
| 4 | BCX-1470 | Discontinued in Phase 1 | |||
| 5 | CVS-1123 | Discontinued in Phase 1 | |||
| 6 | Licostinel | Discontinued in Phase 1 | |||
| 7 | UK-156406 | Discontinued in Phase 1 | |||
| 8 | BMS-189664 | Terminated | |||
| 9 | DuP 714 | Terminated | |||